Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

2024 Annual Meeting | C25 - Motor Neuron Disease

Saturday 04/13/24
02:30 PM - 04:30 PM MDT Add To Calendar
Colorado Convention Center | Bluebird 2E-H
This program will be presented both in-person and online
This program will be available in the meeting's On Demand product.
Seminar
Stephen Goutman, MD, FAAN
Neuromuscular and Clinical Neurophysiology (EMG)
Participants should become familiar with ALS epidemiology, clinical presentations, diagnosis, and clinical management and treatment; learn about the emerging role of genetic testing in ALS for understanding disease risk and for personalized therapeutics; and become familiar with expanded access studies.
 
This program is supported in part by an educational grant from Amylyx Pharmaceuticals, Inc.
2.00 CME credits
Patient Care & Procedural Skills, Medical Knowledge
Intermediate
Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Medical Student
Didactic, Audience Participation

Program Materials Program Evaluations

Event Timeline
02:30 PM - 03:00 PM MDT Speaker ALS Epidemiology, Presentation, Diagnosis, and Treatment
Stephen Goutman, MD, FAAN
03:00 PM - 03:30 PM MDT Speaker The Approach to Genetics and Genetic Testing in ALS
Matthew Harms, MD
03:30 PM - 04:00 PM MDT Speaker The Emergence of Expanded Access Protocols in ALS
Suma Babu, MD, MPH
04:00 PM - 04:30 PM MDT Q&A Questions & Answers
Stephen Goutman, MD, FAAN, Suma Babu, MD, MPH, Matthew Harms, MD
Faculty Disclosures
Matthew Harms, MD Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. Dr. Harms has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Muscular Dystrophy Association. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Invitae. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Variant Bio. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amylyx. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for uniQure. Dr. Harms has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Littlepage Booth. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for O'Connor First. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Searcy Denney. Dr. Harms has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Ford, Parshall & Baker LLC . The institution of Dr. Harms has received research support from ALS Association. The institution of Dr. Harms has received research support from Ionis. The institution of Dr. Harms has received research support from ALS Finding a Cure. The institution of Dr. Harms has received research support from Target ALS.
Stephen Goutman, MD, FAAN Dr. Goutman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Evidera. The institution of Dr. Goutman has received research support from National Institutes of Health. The institution of Dr. Goutman has received research support from ALS Association. The institution of Dr. Goutman has received research support from CDC. Dr. Goutman has received intellectual property interests from a discovery or technology relating to health care.
Suma Babu, MD, MPH The institution of Dr. Babu has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for OrphAI therapeutics. The institution of Dr. Babu has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen. The institution of Dr. Babu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Uniqure Therapeutics. Dr. Babu has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Medscape. The institution of Dr. Babu has received research support from Biogen. The institution of Dr. Babu has received research support from Novartis. The institution of Dr. Babu has received research support from Ionis. The institution of Dr. Babu has received research support from OrphAI therapeutics. The institution of Dr. Babu has received research support from Denali Therapeutics. Dr. Babu has a non-compensated relationship as a Appointed Member of the Committee on ALS: Accelerating Treatments and Improving Quality of Life with National Academies of Sciences, Engineering and Medicine that is relevant to AAN interests or activities.